Your browser doesn't support javascript.
loading
Improving Adherence to Adjuvant Hormonal Therapy Among Disadvantaged Women Diagnosed with Breast Cancer in South Carolina: Proposal for a Multimethod Study.
Felder, Tisha M; Heiney, Sue P; Hebert, James R; Friedman, Daniela B; Elk, Ronit; Franco, Regina; Gansauer, Lucy; Christensen, Barbara; Ford, Marvella E.
  • Felder TM; College of Nursing, University of South Carolina, Columbia, SC, United States.
  • Heiney SP; Cancer Prevention & Control Program, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States.
  • Hebert JR; College of Nursing, University of South Carolina, Columbia, SC, United States.
  • Friedman DB; Cancer Prevention & Control Program, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States.
  • Elk R; Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States.
  • Franco R; Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States.
  • Gansauer L; Office for the Study of Aging, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States.
  • Christensen B; Center for Palliative and Supportive Care, Division of Geriatrics, Gerontology, and Palliative Care, University of Alabama-Birmingham School of Medicine, Birmingham, AL, United States.
  • Ford ME; Center for Integrative Oncology & Survivorship, Cancer Institute, Prisma Health, Greenville, SC, United States.
JMIR Res Protoc ; 9(9): e17742, 2020 Sep 03.
Article en En | MEDLINE | ID: mdl-32880374
ABSTRACT

BACKGROUND:

Current clinical guidelines recommend that hormone receptor-positive breast cancer survivors take adjuvant hormonal therapy (AHT) for 5 to 10 years, following the end of definitive treatment. However, fewer than half of patients adhere to the guidelines, and suboptimal adherence to AHT is associated with an increased risk of breast cancer mortality. Research has extensively documented sociodemographic and disease-specific factors associated with adherence to AHT, but very little evidence exists on behavioral factors (eg, knowledge, patient-provider communication) that can be modified and targeted by interventions.

OBJECTIVE:

The goal of this study is to develop and test a theory-based, multilevel intervention to improve adherence to AHT among breast cancer survivors from racially and socioeconomically disadvantaged backgrounds (eg, Medicaid-insured). The specific aims are to (1) explore multilevel (eg, patient, health care system) factors that influence adherence to AHT; (2) develop a theory-based, multilevel intervention to improve adherence to AHT; and (3) pilot test and evaluate the intervention developed in Aim 2.

METHODS:

For Aim 1, we will recruit breast cancer survivors and health care professionals to participate in semistructured interviews to gain their perspectives about barriers and facilitators to AHT use. We will conduct a directed content analysis of the Aim 1 qualitative interview data. For Aim 2, we will integrate Aim 1 findings and current literature into the design of a multilevel intervention using an Intervention Mapping approach. For Aim 3, we will recruit Medicaid-insured breast cancer survivors to assess the feasibility of the pilot intervention.

RESULTS:

From May 2016 to July 2018, we completed interviews with 19 breast cancer survivors and 23 health care professionals in South Carolina. We will conduct a directed content analysis of the qualitative interview data. Results from this analysis will be used, in combination with current literature, to design (Aim 2) and pilot test a theory-based multilevel intervention (Aim 3) in Summer 2021. Results of the pilot are expected for Fall 2021.

CONCLUSIONS:

This study will provide a deeper understanding of how to improve adherence to AHT, using a novel and multilevel approach, among socioeconomically disadvantaged breast cancer survivors who often experience disproportionate breast cancer mortality. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/17742.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies / Qualitative_research Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies / Qualitative_research Idioma: En Año: 2020 Tipo del documento: Article